News
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten program for Becker and Duchenne muscular ...
DEAR ABBY: I live in a very small town. My husband died a year ago, and since then I have felt like some of these people are ...
Ambiance Boutique in San Luis Obispo, California, faces aggression after being falsely linked to ICE raids at a similarly-named business in Los Angeles.
Ironheart's first three episodes are a thoughtful exploration of grief with an utterly charming performance from Dominique ...
Investing.com - H.C. Wainwright has initiated coverage on Edgewise Therapeutics (NASDAQ: EWTX) with a Buy rating and a price target of $42.00, highlighting the company’s innovative approaches to ...
In other recent news, Edgewise Therapeutics reported first-quarter 2025 financial results that met analyst expectations, with a net loss of $40.8 million, or $0.43 per share.
About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
A high-level overview of Edgewise Therapeutics, Inc. (EWTX) stock. View (EWTX) real-time stock price, chart, news, analysis, analyst reviews and more.
Understand the cash flow statement for Edgewise Therapeutics, Inc. (EWTX), learn where the money comes from and how the company spends it.
Stay up to date on how Edgewise Therapeutics Inc (EWTX:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.
Review quarterly and annual revenue, net income, and cash flow for Edgewise Therapeutics Inc (EWTX:XNAS) stock through the last fiscal year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results